TRX-318 (ImmuNess/Harvard Medical School)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTRX-318 (ImmuNess/Harvard Medical School)
Drug Alias Nameanti-CD3 mAb (NasVax/Harvard Medical School)TRX-318 (OrImmune/Harvard Medical School)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHarvard Medical School
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOrImmune BioHarvard Medical SchoolSciSparc Ltd
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A